EDINBURGH MOLECULAR IMAGING
See. Treat. Cure.
Highly Specific Cancer Targeting
Using its proprietary platform technology, EM Imaging is developing a pipeline of highly novel in vivo c-Met targeting theragnostic and optical imaging agents that will alter the landscape of precision medicine.
Pipeline
EM Imaging has a portfolio of agents addressing a number of unmet medical needs.
Ongoing Clinical Studies
EM Imaging is focused on the development of fluorescent optical imaging and therapeutic agents. Our current clinical trials are detailled in a dedicated section.
Latest Press Release
Edinburgh Molecular Imaging Appoints Bernhard Sixt as new Chief Executive Officer
Seasoned CEO with 30 years’ experience in the healthcare industry Edinburgh, United Kingdom - 8 November 2018 – Edinburgh Molecular Imaging (EM Imaging), the optical molecular imaging company,...
Our Latest News
Edinburgh Molecular Imaging announce Bowel Cancer UK and Beating Bowel Cancer as charity partner
Bowel Cancer UK and Beating Bowel Cancer announced as Edinburgh Molecular (EM) Imaging’s Charity partner. EM Imaging, based in Edinburgh, is partnering with Bowel Cancer UK and Beating Bowel Cancer...
Edinburgh Molecular Imaging Commences Phase II European Cancer Trial
Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh, UK – 19 September 2017: Edinburgh Molecular Imaging (EM Imaging), the clinical phase...